Biotechnology

A massive financing round for deupirfenidone isn't just about a potential new IPF drug; it's a masterclass in biotech strategy, validating a model that promises value for all.

Molecular Partners and Orano Med begin human trials for a novel radiopharmaceutical, hoping to unlock a new front against small cell lung cancer.

A new study for CRENESSITY could revolutionize care for infants with classic congenital adrenal hyperplasia, shifting the treatment paradigm and solidifying market leadership.

With a platform 300x faster than traditional methods, Hill Research has secured a major follow-on investment, signaling a new era for AI in life sciences.

For women with resistant ovarian cancer, options are few. A new drug, NTB-928, uses a dual-key design to unlock the immune system against tumors.

Rentschler Biopharma appoints Dr. Torsten Woehr as CEO, a strategic move to deepen its core biologics focus after exiting cell and gene therapy.

A surge in biotech innovation is set to transform the high-grade glioma market. With a pipeline of targeted drugs and vaccines, a once-stagnant field is now a beacon of hope.

Oryzon Genomics secures a dual funding package, navigating market jitters to accelerate its pioneering cancer and psychiatric drug pipelines with EU backing.

Artelo's latest data on its non-opioid pain drug ART26.12 could unlock a massive market, but what are the real risks and rewards for this clinical-stage biotech?

Vyome Holdings secures a key patent in China, not by betting the farm, but by making a shrewd, capital-efficient move to tap into a massive future market.

A biotech firm is using the ISS to build artificial retinas, bypassing Earth's gravity to create a potential cure for millions facing blindness.

A company trading in fractions of a penny executes an extreme reverse stock split. Is this a desperate act of financial engineering or a strategic pivot?

Intensity Therapeutics shows promising results for its cancer-killing drug, but can it navigate the biotech funding crunch and land a vital pharma partner?

As biotech firm Seer secures key patent wins, it's not just defending its tech—it's drawing the battle lines for the multi-billion dollar proteomics market.

As Sobi prepares its Q2 2026 report, all eyes are on its booming immunology unit. After a stellar Q1, the key test is sustaining that momentum.

New imaging data provides the first evidence that a drug-app combo for Parkinson's can induce physical changes in the brain, linking digital therapy to better outcomes.

Galderma's innovative neuromodulator, a key to its 'powerhouse' ambitions, hits a U.S. roadblock. The FDA's concerns? Manufacturing, not safety.

The FDA approved Orca Bio's revolutionary cell therapy, promising better outcomes for cancer patients. But the real test lies beyond the science.

4D Molecular Therapeutics is set to reveal 2-year data on a potential one-time gene therapy for wet AMD, a move that could end the relentless cycle of eye injections.